Takeda launches Edarbyclor
DEERFIELD, Ill. — Takeda Pharmaceutical has launched a drug for treating high blood pressure in adults, the company said.
Takeda announced the availability of Edarbyclor (azilsartan medoxomil and chlorthalidone), a once-daily tablet for the condition, also known as hypertension.
"February is American Hearth Month, and it’s important to recognize that nearly 40% of hypertension patients are not at their blood pressure targets, putting them at increased cardiovascular risk," Takeda Pharmaceuticals U.S.A. president Douglas Cole said. "We’re pleased to bring Edarbyclor to market and expand the Edarbi family of products to help appropriate patients with hypertension work towards reaching their blood pressure goals."
No comments found
Todd Mitchell appointed president of Crossmark’s U.S. sales agency
PLANO, Texas — A Crossmark EVP is taking on a new role at the company.
Todd Mitchell, who has worked at Crossmark for more than 12 years, now will serve as president of the company’s U.S. sales agency. Ben Fischer, who served as COO and president of Crossmark’s U.S. sales agency now will solely focus on his COO duties, the company said.
Crossmark’s U.S. operations are divided into a marketing services division and a sales agency division.
“We believe these moves demonstrate our continuing assurance of providing service excellence and our commitment to helping our clients achieve their goals,” Crossmark CEO John Thompson said.
No comments found
CDC study: Number of TFAs in blood levels on decline
ATLANTA — The amount of trans fats found in blood levels of U.S. white adults has significantly dropped over a nine-year period, according to a study conducted by the Centers for Disease Control and Prevention.
The study, published in the Feb. 8 edition of the Journal of the American Medical Association pooled participants from the CDC’s National Health and Nutrition Examination Survey in 2000 and 2009. The goal was to examine trans-fatty acid blood levels among this demographic before and after the Food and Drug Administration’s 2003 regulation — which took effect in 2006 — that required manufacturers to list the amount of TFAs on the Nutrition Facts panel of a food or dietary supplement product label. The researchers found that TFAs found in blood levels decreased by 58%. The consumption of trans fats increases the risk of coronary heart disease, the CDC noted.
Full details of the study can be viewed here.
"The 58% decline shows substantial progress that should help lower the risk of cardiovascular disease in adults," said Christopher Portier, director of CDC’s National Center for Environmental Health. "Findings from the CDC study demonstrate the effectiveness of these efforts in reducing blood TFAs and highlight that further reductions in the levels of trans fats must remain an important public health goal."
Portier added that while the study only provides information regarding TFAs among white adults, additional CDC studies are under way to examine blood TFAs in other adult race/ethnic groups, children and adolescents.
Great to see we're eating less, but looks like the only safe intake is zero: nutritionfacts.org/videos/trans-fat-saturated-fat-and-cholesterol-tolerable-upper-intake-of-zero/